CMS to Consider Evidence on Bone Growth Agent

WASHINGTON (MedPage Today) — The Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) will meet in September to consider available evidence for using bone morphogenetic (BMP) for a number of on-label and off-label uses.


Read more

Related posts

Leave a Reply